結節性癢疹治療市場機會、成長動力、產業趨勢分析及 2025 - 2034 年預測

2024年，全球結節性癢疹治療市場規模達21億美元，預計2034年將以4.1%的複合年成長率成長，達到31億美元。這種穩定成長源自於多種相互關聯的因素。全球越來越多的人被診斷出患有結節性癢疹(PN)，這是一種慢性劇烈搔癢的皮膚病，常發於20至60歲的成年人。 PN與潛在的全身性疾病（包括肝臟、腎臟和神經系統疾病）的關聯日益密切，這進一步推動了對有效療法的需求。

推動需求成長的另一個因素是疾病的致殘性，它嚴重影響生活品質，並且通常需要長期治療。隨著認知度的提高，患者和醫護人員都更傾向於尋求不僅針對症狀，更能解決病因的醫療解決方案。近年來，製藥公司加大了對旨在打破搔癢-抓撓循環並緩解慢性皮膚發炎的療法研發的投資。針對腸外營養不良症（PN）潛在機制的創新生物製劑正在逐漸改變治療格局，與傳統療法相比，它們能夠提供更有針對性、更持久的療效。

來自私人投資者和公共醫療計劃的資金湧入，為未來的發展奠定了堅實的基礎。這些資源推動了生物製劑療法的上市和開發，這些療法已在臨床研究中顯示出良好的療效。新的標靶治療方案的出現正在改變處方醫生的行為，生物製劑逐漸成為治療模式的首選。隨著更多先進療法獲得監管部門批准並進入市場，這一趨勢預計將進一步加速。

結節性癢疹治療市場涵蓋多種旨在控制發炎、搔癢和皮膚病變的藥物，包括皮質類固醇、抗組織胺、潤膚劑、辣椒素乳膏和生物製劑。其中，皮質類固醇在2024年佔據全球市場首位，價值達6.504億美元。其廣泛應用可歸因於其強大的抗發炎作用、價格實惠且易於取得。皮質類固醇通常用作第一線治療藥物，用於短期發作和輕度至中度腸外營養不良的長期管理。皮質類固醇有處方藥和非處方藥兩種形式，這增加了其吸引力，使其成為門診護理和自我管理的首選藥物。

2024年，局部治療佔了55.3%的市場佔有率，凸顯了其在局部症狀管理中的作用。這些療法的優點在於能夠直接針對受影響的皮膚區域進行標靶給藥，從而最大限度地減少全身暴露和副作用。潤膚劑、皮質類固醇乳膏和辣椒素類製劑等產品是常用產品，因其使用方便且價格相對較低而備受青睞。這些產品在醫療保健機構和零售藥局均易於獲取，這鞏固了它們持續的主導地位。

處方藥類別有望實現顯著成長，預計預測期內複合年成長率將達到 3.8%。這一細分市場的成長動力源自於醫生監督治療方案的轉變，以及免疫抑制劑、鈣調磷酸酶抑制劑和生物製劑等高效能藥物的日益普及。隨著越來越多的患者就診於腸外營養 (PN) 的嚴重症狀，對處方藥的需求也不斷成長。生物製劑尤其助長了這一勢頭，因為它們能夠提供長期控制，並且專為需要持續醫療監督的複雜病例而設計。

醫院藥局在2024年佔據領先地位，預計到2034年將達到16億美元。這些機構在生物製劑和注射用皮質類固醇等特殊療法的配藥方面發揮著至關重要的作用，尤其對於接受持續治療或治療嚴重腸外營養不良（PN）的患者而言。它們通常採用集中採購系統，從而簡化高價藥物的取得。此外，它們與皮膚科和免疫科的整合確保了適當的治療監測和劑量依從性，使其成為晚期腸外營養治療的關鍵配銷通路。

2024年，北美以41.3%的市佔率領先全球市場，其中美國就佔據了8.166億美元的市場。該地區的成長得益於其發達的醫療保健體系、較高的診斷率以及尖端治療手段的可及性。隨著越來越多的患者在臨床環境中接受評估，以及相關意識提升措施的推進，對先進療法的需求持續成長。

競爭格局正在改變。雖然抗組織胺和皮質類固醇等傳統療法依然佔據主導地位，但生物製劑的進入已開始重塑治療模式。製藥巨頭和生技公司都專注於開發針對特定疾病的療法，推動了治療向長期、系統性治療的轉變，而這種治療不僅限於緩解症狀。因此，在監管框架和商業基礎設施完善的地區，市場競爭正在加劇。

目錄

第1章：方法論與範圍

第2章：執行摘要

第3章：行業洞察

• 產業生態系統分析
  • 供應商格局
  • 每個階段的增值
  • 影響價值鏈的因素
• 產業衝擊力
  • 成長動力
    • 結節性癢疹盛行率不斷上升
    • 藥物創新和批准不斷增加
    • 提高對疾病的認知和皮膚科諮詢的可近性
  • 產業陷阱與挑戰
    • 生物療法成本高昂
    • 與某些藥物相關的副作用
  • 市場機會
    • 以患者為中心的數位健康解決方案的採用率不斷提高
    • 新型生物製劑的開發
• 成長潛力分析
• 監管格局
• 未來市場趨勢
• 管道分析
• 波特的分析
• PESTEL分析

第4章：競爭格局

• 介紹
• 公司市佔率分析
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 關鍵進展
  • 併購
  • 夥伴關係與協作
  • 新產品發布
  • 擴張計劃

第5章：市場估計與預測：依產品類型，2021 年至 2034 年

• 主要趨勢
• 皮質類固醇
• 抗組織胺藥
• 潤膚劑
• 辣椒素乳膏
• 生物製劑
• 鈣調神經磷酸酶抑制劑
• 免疫抑制劑
• 其他產品類型

第6章：市場估計與預測：依管理路線，2021 年至 2034 年

• 主要趨勢
• 外用
• 口服
• 注射劑

第7章：市場估計與預測：依藥物類型，2021 年至 2034 年

• 主要趨勢
• 處方
• 場外交易

第8章：市場估計與預測：按配銷通路，2021 年至 2034 年

• 主要趨勢
• 醫院藥房
• 零售藥局
• 網路藥局

第9章：市場估計與預測：按地區，2021 年至 2034 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 義大利
  • 西班牙
  • 荷蘭
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第10章：公司簡介

• Bayer
• Galderma
• GlaxoSmithKline
• Johnson & Johnson
• Merck
• Pfizer
• Rugby Pharma
• Sanofi
• Takeda Pharmaceuticals
• Teva Pharmaceutical Industries
• Trevi Therapeutics
• VYNE Therapeutics

The Global Prurigo Nodularis Treatment Market was valued at USD 2.1 billion in 2024 and is estimated to grow at a CAGR of 4.1% to reach USD 3.1 billion by 2034. This steady growth stems from various interrelated factors. A rising number of individuals across the globe are being diagnosed with prurigo nodularis (PN), a chronic and intensely itchy skin condition that often develops in adults between the ages of 20 and 60. PN has been increasingly associated with underlying systemic disorders, including liver, kidney, and neurological conditions, which has further driven the need for effective therapies.

What's also driving the demand is the debilitating nature of the disease, which severely affects the quality of life and often demands long-term treatment. As awareness grows, both patients and medical professionals are more inclined to pursue medical solutions that target not only the symptoms but also the root causes of the condition. In recent years, pharmaceutical companies have ramped up investments in the research and development of therapies that aim to break the itch-scratch cycle and mitigate chronic skin inflammation. Innovative biologics targeting the underlying mechanisms of PN are gradually changing the landscape of care, offering more targeted and durable outcomes compared to traditional therapies.

The influx of funding from private investors and public healthcare initiatives has provided a solid foundation for future advancements. These resources are enabling the launch and development of biologic-based treatments that have demonstrated promising results in clinical studies. The availability of new targeted options is shifting prescriber behavior, with biologics gradually becoming a preferred choice in the treatment paradigm. This trend is expected to further accelerate as more advanced therapies gain regulatory approval and enter the market.

The market for prurigo nodularis treatment includes a wide range of medications aimed at managing inflammation, itch, and skin lesions. These include corticosteroids, antihistamines, emollients, capsaicin creams, and biologics. Among these, corticosteroids led the global market in 2024, with a value of USD 650.4 million. Their widespread use can be attributed to their strong anti-inflammatory effects, affordability, and accessibility. Often used as first-line therapy, corticosteroids are prescribed for both short-term flare-ups and long-term management of mild to moderate PN. Their availability in both prescription and over-the-counter formats adds to their appeal, making them a go-to option for outpatient care and self-management.

Topical treatments accounted for 55.3% of the market share in 2024, highlighting their role in localized symptom management. These therapies offer the advantage of targeted application directly to affected skin areas, minimizing systemic exposure and adverse effects. Products such as emollients, corticosteroid creams, and capsaicin-based formulations are commonly used and are favored for their ease of use and relatively low cost. Their accessibility through both healthcare providers and retail pharmacies reinforces their continued dominance.

The prescription drug category is poised for notable growth, expected to expand at a CAGR of 3.8% over the forecast period. This segment is being driven by a shift toward physician-supervised treatment plans and the increasing use of high-efficacy drugs like immunosuppressants, calcineurin inhibitors, and biologics. As more patients seek medical consultation for PN's severe symptoms, the demand for prescription-only therapies is rising. Biologic agents in particular are contributing to this momentum, as they offer long-term control and are specifically designed for complex cases requiring consistent medical oversight.

Hospital pharmacies held a leading position in 2024 and are projected to reach USD 1.6 billion by 2034. These facilities play a crucial role in dispensing specialized therapies such as biologics and injectable corticosteroids, particularly for patients undergoing continuous treatment or managing severe PN. They often operate under centralized procurement systems that allow for streamlined access to high-cost medications. Moreover, their integration with dermatology and immunology departments ensures proper treatment monitoring and dosage adherence, making them a key distribution channel for advanced PN care.

North America led the global market with a 41.3% share in 2024, with the United States alone accounting for USD 816.6 million. Growth in this region is supported by a well-developed healthcare system, high diagnosis rates, and access to cutting-edge treatments. The demand for advanced therapies continues to grow as more patients are evaluated in clinical settings and awareness initiatives gain traction.

The competitive landscape is transforming. While traditional therapies such as antihistamines and corticosteroids continue to have a presence, the entry of biologics has begun to reshape treatment dynamics. Pharmaceutical leaders and biotech firms alike are focused on the development of disease-specific therapies, creating a shift toward long-term, systemic treatments that go beyond symptom relief. As a result, market competition is intensifying in regions with strong regulatory frameworks and commercial infrastructures.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Regional
  • 2.2.2 Product type
  • 2.2.3 Route of administration
  • 2.2.4 Medication type
  • 2.2.5 Distribution channel
• 2.3 CXO perspectives: Strategic imperatives
  • 2.3.1 Key decision points for industry executives
  • 2.3.2 Critical success factors for market players
• 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
  • 3.1.1 Supplier landscape
  • 3.1.2 Value addition at each stage
  • 3.1.3 Factors affecting the value chain
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of prurigo nodularis
    • 3.2.1.2 Growing innovation and approval of medications
    • 3.2.1.3 Rising awareness of disease and accessibility to dermatology consultation
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of biologic therapies
    • 3.2.2.2 Side effects associated with certain drugs
  • 3.2.3 Market opportunities
    • 3.2.3.1 Increased adoption of patient-centric digital health solutions
    • 3.2.3.2 Development of novel biologics
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
  • 3.4.4 Latin America
  • 3.4.5 Middle East and Africa
• 3.5 Future market trends
• 3.6 Pipeline analysis
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Corticosteroids
• 5.3 Antihistamines
• 5.4 Emollients
• 5.5 Capsaicin cream
• 5.6 Biologics
• 5.7 Calcineurin inhibitors
• 5.8 Immunosuppressants
• 5.9 Other product types

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Topical
• 6.3 Oral
• 6.4 Injectable

Chapter 7 Market Estimates and Forecast, By Medication Type, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Prescription
• 7.3 OTC

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Hospital pharmacies
• 8.3 Retail pharmacies
• 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Italy
  • 9.3.5 Spain
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Bayer
• 10.2 Galderma
• 10.3 GlaxoSmithKline
• 10.4 Johnson & Johnson
• 10.5 Merck
• 10.6 Pfizer
• 10.7 Rugby Pharma
• 10.8 Sanofi
• 10.9 Takeda Pharmaceuticals
• 10.10 Teva Pharmaceutical Industries
• 10.11 Trevi Therapeutics
• 10.12 VYNE Therapeutics